Genova Biotech To Launch New Anti-cancer Drug Novaferon
This article was originally published in PharmAsia News
Beijing-based Genova Biotech will complete clinical trials on its anti-cancer drug Novaferon and commence production within the year. The company disclosed that it will price the genetically engineered protein-based product at a level only one-fifth to one-tenth that of imported biopharmaceutical medicines. Although it is still in the final approval stages, the drug's projected sales could reach several billion yuan. Novaferon's anti-tumor and anti-virus activities are much higher than those of natural interferon. Trials show that the drug can inhibit the growth of cancer of the pancreas, bowel, liver, lung, breast, ovary and prostate. (Click here for more - Chinese Language)
You may also be interested in...
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.